Vaxart presents at Vaccine & ISV Congress in Seoul
The presentations will include information from the company’s two studies of these products. One will include data that shows the oral norovirus vaccine provokes a wider immune response than an injectable VLP VP1 vaccine. Another will emphasize data results from a Phase 1 clinical study that shows just one dose of the company’s H1N1 influenza tablet vaccine produced neutralizing antibodies within 92 percent of the study’s subjects.
Leesun Kim, a scientist from Vaxart, presented “Oral Immunization of a Norovirus Vaccine Leads to Superior Specific IgA Responses in Animals” Sunday and “Tablet Vaccine Platform Elicits Neutralizing Antibodies Without Impact on Pre-existing Immunity” Tuesday.
Vaxart has designed its vaccines to be founded on a versatile vector-based platform. The vaccines are meant to be used for a broad range of diseases including tablet vaccine candidates for norovirus, seasonal influenza, and Respiratory Syncytial Virus.